Ipratropium bromide acts selectively on bronchial muscle without altering the volume or consistency of respiratory secretions. Another desirable feature is that in contrast to atropine, it does not depress mucociliary clearance by bronchial epithelium. ipratropium is more effective in COPD(chronic obstructive pulmonary disease) than in bronchial asthma.
As per the best practices of the company, we assure you that the information provided herein is factual,
truthful, up-to-date, and complete. It is very important to note that this report should not be used in lieu
of physical medical consultation/advice. We do not guarantee the authenticity or credibility of the
data/information presented. The absence of any details and/or warning/notice to any drugs & medicine
shall not be deemed or assumed to be an implied assurance of the Company. We accept no
responsibility for the consequences due to the aforementioned data/information and in case of any
doubts or queries, we strongly advise you to seek a physical consultation.